Top-News
Dienstag,
13.08.2013 03:30
von
PR Newswire
| Aufrufe: 56
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
E-Health-Software auf einem Smartphone (Symbolbild).
© cnythzl/ iStock / Getty Images Plus/ Getty Images
http://www.gettyimages.de
PR Newswire
IRVINE, Calif., Aug. 12, 2013
IRVINE, Calif., Aug. 12, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented three "smart medical devices" which have similar purpose; to give physicians advanced situational awareness during critical procedures and thus cutting cost to providers and risk to patients. These three devices are next for FDA 510k clearance. "EPGL is a company that is amassing advanced device technologies at a rapid pace and will make its mark with development of smarter medical devices." said David T. Markus PhD. "We have the advantage in advanced MEMS technology and this is the field that will revolutionize medicine in the next several years. EPGL shareholders are in a very special company at a special time."
1. MEMS Epidural Needle Device
EPGL Medical has invented a smart needle for procedures involving injection of any substance into the epidural space. These procedures require a physician to be technically proficient in order to avoid complications. Practitioners commonly use air or saline for identifying the epidural space. However, EPGL Medical is using TopSpin micron movement precision technology with advanced sensors to give the physician better situational awareness during the procedure.
Physicians have to take great care to avoid puncturing the layer adjoining the epidural space which contains cerebrospinal fluid under pressure. If they were to puncture this while threading the needle between vertebras into the epidural space, it could cause complications for the patient. EPGL's smart device will help doctors have much greater situational awareness for this procedure.
2. MEMS Nerve Ablation Device
EPGL Medical has invented a smarter nerve ablation device. Radio Frequency Ablation (RFA), is used to produce heat on nerves surrounding the facet joints on either side of the lumbar spine. This procedure eliminates the ability for the nerve to transmit pain signals to the brain, thus giving the patient temporary relief. In similar fashion to the smart epidural needle mentioned above, the EPGL trigger point treatment device advances this ablation tool with TopSpin precision and sensors, giving the physician better situational awareness during the procedure and thus less risk of complications.
3. MEMS Trigger Point Needle Device
EPGL Medical has invented a more accurate needle device for treatment of myofascial trigger points. Injections for trigger points can be dry or include saline, local anesthetics such as steroids procaine hydrochloride, lidocaine, and botulinum toxin to provide more immediate relief and can be effective when other methods fail. However, physicians will have a better, more accurate needling device for treatment of trigger points. The new device will employ advanced MEMS technology sensors through a TopSpin platform, to more accurately identify the dimensions and perimeter of the myofascial trigger points to be injected. The MPD1 is to stimulate the trigger points and the new MPT1 device will better treat the trigger points.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board. The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development. The Company is the owner of the cutting edge technological platform for medical device development called "Topspin."
RELATED LINKS
http://www.epglmed.com
SOURCE EPGL Medical
Werbung
Mehr Nachrichten zur EP GLOBAL COMMUNICAT Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Andere Nutzer interessierten sich auch für folgende News
14:00 - wallstreet:online ...
